FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain

myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician DUBLIN - October 24, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration ... Devices, Drug Delivery, Neurology, FDA Medtronic, SynchroMed II, myPTM, Personal Therapy Manager, pain pump

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044465

Source: HSMN NewsFeed - October 24, 2018 Category: Pharmaceuticals Source Type: news

More News: Brain | Food and Drug Administration (FDA) | Neurology | Pain | Pharmaceuticals